russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2020-3861russjcardiol-3861Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON THE ISSUEАнгиотензин II и COVID-19. Тайны взаимодействийAngiotensin II and COVID-19. Secrets of interactionshttps://orcid.org/0000-0001-8169-7812КонрадиА. О.KonradiA. O.

Конради Александра Олеговна — доктор медицинских наук, профессор, член-корреспондент РАН; заместитель генерального директора по научной работе; руководитель НИО артериальной гипертензии; директор Института трансляционной медицины, Университет ИТМО

Санкт-Петербург

konradi@almazovcenre.ruhttps://orcid.org/0000-0001-8892-6411НедошивинА. О.NedoshivinA. O.

Недошивин Александр Олегович — ученый секретарь, доктор медицинских наук, профессор

Санкт-Петербург

konradi@almazovcenre.ruФГБУ НМИЦ им. В.А. Алмазова Минздрава РоссииРоссияAlmazov National Medical Research CenterRussian Federation20202604202025438613861Copyright © Конради А.О., Недошивин А.О., 20202020Конради А.О., Недошивин А.О.Konradi A.O., Nedoshivin A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/3861

Статья посвящена актуальным данным о связи ренин-ангиотензиновой системы и применения препаратов, влияющих на ее активность с риском заражения и рисками исходов при COVID-19 инфекции. Приведен анализ последних данных литературы и сделан вывод об отсутствии связи приема ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов к ангиотензину II c каким-либо риском негативного исхода и отсутствии показаний к отмене этих групп препаратов.

The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes. Analysis of the latest publications did not reveal association of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with any risk of an unfavorable outcomes, and there was no data for withdrawal of these drugs.

COVID-19ингибиторы ангиотензинпревращающего ферментаангиотензинпревращающий фермент 2 типаCOVID-19angiotensin converting enzyme inhibitorsangiotensin converting enzyme 2ReferencesHFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatement-addresses-concerns-re-using-raas-antagonists-in-covid-19.HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatement-addresses-concerns-re-using-raas-antagonists-in-covid-19.ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. last updated on 21 April 2020, https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-GuidanceESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. last updated on 21 April 2020, https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-GuidanceШляхто Е.В. Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801.Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505- 53. doi:10.1152/physrev.00023.2016.Santos RAS, Sampaio WO, Alzamora AC, et al. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018;98(1):505- 53. doi:10.1152/physrev.00023.2016.Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation. 2005;111(20):2605-10. doi:10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin‐converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin‐converting enzyme 2. Circulation. 2005;111(20):2605-10. doi:10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.Sommerstein R, Gräni C. Rapid response: re: preventing a covid‐19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid‐19. BMJ 2020; 368. doi:10.1136/bmj.m810.Sommerstein R, Gräni C. Rapid response: re: preventing a covid‐19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid‐19. BMJ 2020; 368. doi:10.1136/bmj.m810.Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID19 pandemic? J Hypertens. 2020;38(5):781-2. doi:10.1097/HJH.0000000000002450.Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID19 pandemic? J Hypertens. 2020;38(5):781-2. doi:10.1097/HJH.0000000000002450.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi:10.1002/path.1570.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi:10.1002/path.1570.Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoVInduced Acute Lung Injury. Virol Sin. 2020. doi:10.1007/s12250-020-00205-6. Online ahead of print.Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoVInduced Acute Lung Injury. Virol Sin. 2020. doi:10.1007/s12250-020-00205-6. Online ahead of print.Guang Ya, Zihu T, Ling Z, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. doi:10.1101/2020.03.31.20038935.Guang Ya, Zihu T, Ling Z, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. doi:10.1101/2020.03.31.20038935.Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. NEJM. 2020;382(17):1653-9. doi:10.1056/NEJMsr2005760.Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. NEJM. 2020;382(17):1653-9. doi:10.1056/NEJMsr2005760.Sommerstein R, Kochen MM, Messerli FH, Gräni Ch. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.016509.Sommerstein R, Kochen MM, Messerli FH, Gräni Ch. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.016509.Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x.Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234. doi:10.1186/s13054-017-1823-x.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054- 62. doi:10.1016/S0140-6736(20)30566-3.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054- 62. doi:10.1016/S0140-6736(20)30566-3.Juyi Li, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1624.Juyi Li, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.1624.Zoler ML. ACEI/ARBs Linked With Survival in Hypertensive, Chinese COVID-19 Patients Medscape. Medical News April 22. 2020.Zoler ML. ACEI/ARBs Linked With Survival in Hypertensive, Chinese COVID-19 Patients Medscape. Medical News April 22. 2020.Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. doi:10.1002/ddr.21656. Online ahead of print.Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. doi:10.1002/ddr.21656. Online ahead of print.

The authors declare that there are no conflicts of interest present.